Pancreatic Cancer Detection Consortium
Recruiting · NCT06388967 · Observational (researchers observe without assigning treatment) · Lead sponsor: City of Hope Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
PANcreatic cancer Exosome Early detectiON (PANXEON)
What this trial is about
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)
- Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
- Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)
Exclusion criteria
- Lack of written informed consent.
Where it is running
11 locations listed across 7 US states.
- Translational Genomics Research Institute - Phoenix, Arizona, United States
- Honorhealth - Scottsdale, Arizona, United States
- City of Hope Medical Center - Monrovia, California, United States
- Hoag Center - Newport Beach, California, United States
- OSF HealthCare - Peoria, Illinois, United States
- Ochsner Medical Center - Jefferson, Louisiana, United States
- Atlantic Health System - Morristown, New Jersey, United States
- Piedmont Medical Center - Rock Hill, South Carolina, United States
- Medical College of Wisconsin - Milwaukee, Wisconsin, United States
- Nagoya University - Nagoya, Japan
- Asan Medical Center - Seoul, South Korea